ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Amgen, Kyowa Kirin and AO GENERIUM side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Amgen×Kyowa Kirin×AO GENERIUM×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AmgenKyowa KirinAO GENERIUM
studies on the registry1,08823231
open to participants now50113
phase 3 studies under way5033
reach primary completion within a year3520
programswith a study of their own in two years24153

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAmgenKyowa KirinAO GENERIUM
Phase 1

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

Kyowa Kirin: 12 of its 15 programs at phase 1

  1. KK2223phase 1
  2. KK2845_1phase 1
  3. KK2845_2phase 1
  4. KK2845_3phase 1
  5. KK2845_4phase 1

and 7 more — sign in to see them all

80%
00%
Phase 2

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

Kyowa Kirin: 2 of its 15 programs at phase 2

  1. KK2430phase 2
  2. ziftomenibphase 2
13%

AO GENERIUM: 1 of its 3 programs at phase 2

  1. GNR-127phase 2
33%
Phase 3

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

Kyowa Kirin: 1 of its 15 programs at phase 3

  1. KK8398phase 3
7%

AO GENERIUM: 2 of its 3 programs at phase 3

  1. afliberceptphase 3
  2. Revelise (GENERIUM, Russia)phase 3
67%
Approved, new studies

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%
00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
Kyowa Kirin2 readouts · 0 phase 3····

Kyowa Kirin, Mar ’27: 1 program whose next study reaches primary completion

  1. ziftomenibphase 2 · Mar 0 · NCT07623616

Kyowa Kirin, Apr ’27: 1 program whose next study reaches primary completion

  1. KK2430phase 2 · Apr 0 · NCT07629726
······
AO GENERIUM0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 5

Kyowa Kirin

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AO GENERIUM

New programs 1

  • afliberceptphase 3 · first study · Sep 18 · Macular Degeneration

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionAmgenKyowa KirinAO GENERIUM
Colorectal Neoplasms2 of 3 · compare here

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

–

AO GENERIUM in Colorectal Neoplasms: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Colorectal Neoplasms in search

Lymphoma, Non-Hodgkin2 of 3 · compare here

Amgen in Lymphoma, Non-Hodgkin: 2 programs

  1. afliberceptphase 3
  2. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, Non-Hodgkin in search

–

AO GENERIUM in Lymphoma, Non-Hodgkin: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Lymphoma, Non-Hodgkin in search

Macular Edema2 of 3 · compare here

Amgen in Macular Edema: 2 programs

  1. afliberceptphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Macular Edema in search

–

AO GENERIUM in Macular Edema: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Macular Edema in search

Macular Degeneration2 of 3 · compare here

Amgen in Macular Degeneration: 1 program

  1. afliberceptphase 3

Their studies: Amgen’s studies of Macular Degeneration in search

–

AO GENERIUM in Macular Degeneration: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Macular Degeneration in search

Myelodysplastic Syndromes2 of 3 · compare here

Amgen in Myelodysplastic Syndromes: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Myelodysplastic Syndromes in search

Kyowa Kirin in Myelodysplastic Syndromes: 1 program

  1. ziftomenibphase 2

Their studies: Kyowa Kirin’s studies of Myelodysplastic Syndromes in search

–
Retinal Vein Occlusion2 of 3 · compare here

Amgen in Retinal Vein Occlusion: 1 program

  1. afliberceptphase 3

Their studies: Amgen’s studies of Retinal Vein Occlusion in search

–

AO GENERIUM in Retinal Vein Occlusion: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Retinal Vein Occlusion in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAmgenKyowa KirinAO GENERIUM
PGFafliberceptrule–afliberceptrule
VEGFAafliberceptrule–afliberceptrule
A target, or a pathogen for a vaccine, known for: Amgen 17 of 24 · Kyowa Kirin 1 of 15 · AO GENERIUM 1 of 3 programs (18 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.